<DOC>
	<DOC>NCT00292721</DOC>
	<brief_summary>Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.</brief_summary>
	<brief_title>Effects of Celecoxib After Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography Acute ST elevation MI Left main disease Contraindications to aspirin, clopidogrel or celecoxib Severe congestive heart failure Expected survival &lt; 2 years Hepatic dysfunction Currently taking NSAIDs or any COX2 inhibitor Renal dysfunction Use of warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>